Insulin-like growth factor-1 and neurotrophin-3 gene therapy prevents motor decline in an X-linked adrenoleukodystrophy mouse model

Annals of Neurology

Volumn 66, Issue 1, 2009, Pages 117-122

  Mastroeni, Roberto ^a   Bensadoun, Jean Charles ^a   Charvin, Delphine ^a   Aebischer, Patrick ^a   Pujol, Aurora ^b,c,d   Raoul, Cédric ^a,e  

^a EPFL   (Switzerland)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^e Turing Center for Living Systems CENTURI Aix Marseille University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ADENOASSOCIATED VIRUS VECTOR HUMAN INSULIN LIKE GROWTH FACTOR 1; ADENOASSOCIATED VIRUS VECTOR HUMAN NEUROTROPHIN 3; ENHANCED GREEN FLUORESCENT PROTEIN; MYELIN; NEUROTROPHIN 3; PARVOVIRUS VECTOR; SOMATOMEDIN C; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ABCD1 GENE; ADRENOLEUKODYSTROPHY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEMYELINATION; DISORDERS OF PEROXISOMAL FUNCTIONS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE; GENE THERAPY; HISTOPATHOLOGY; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; WILD TYPE; X CHROMOSOME LINKED DISORDER;

ADRENOLEUKODYSTROPHY; ANALYSIS OF VARIANCE; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BEHAVIOR, ANIMAL; CHEMOKINE CCL22; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GREEN FLUORESCENT PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; MICE, KNOCKOUT; MOVEMENT DISORDERS; NEUROTROPHIN 3;

EID: 69249088443     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21677     Document Type: Article

References (20)

1. Moser HW, Mahmood A, Raymond GV. X-linked adrenoleukodystrophy. Nat Clin Pract 2007;3:140-151.
2. Berger J, Gartner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006;1763:1721-1732.
3. Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci 1999;22:4-12.
4. Ferrer I, Kapfhammer JP, Hindelang C, et al. Inactivation of the peroxisomal ABCD2 transporter in the mouse leads to lateonset ataxia involving mitochondria, Golgi and endoplasmic reticulum damage. Hum Mol Genet 2005;14:3565-3577.
5. Pujol A, Ferrer I, Camps C, et al. Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 2004; 13:2997-3006.
6. Pujol A, Hindelang C, Callizot N, et al. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum Mol Genet 2002;11: 499-505.
7. Feigenbaum V, Gelot A, Casanova P, et al. Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients. Neurobiol Dis 2000;7:600-612.
8. Hsieh J, Aimone JB, Kaspar BK, et al. IGF-I instructs multipotent adult neural progenitor cells to become oligodendrocytes. J Cell Biol 2004;164:111-122.
9. Jean I, Lavialle C, Barthelaix-Pouplard A, Fressinaud C. Neurotrophin-3 specifically increases mature oligodendrocyte population and enhances remyelination after chemical demyelination of adult rat CNS. Brain Res 2003;972:110-118.
10. Kumar S, Biancotti JC, Yamaguchi M, de Vellis J. Combination of growth factors enhances remyelination in a cuprizone-induced demyelination mouse model. Neurochem Res 2007;32: 783-797.
11. Wilson HC, Onischke C, Raine CS. Human oligodendrocyte precursor cells in vitro: phenotypic analysis and differential response to growth factors. Glia 2003;44:153-165.
12. Ye P, Li L, Richards RG, et al. Myelination is altered in insulin-like growth factor-I null mutant mice. J Neurosci 2002; 22:6041-6051.
13. Fu H, Kang L, Jennings JS, et al. Significantly increased lifespan and improved behavioral performances by rAAV gene delivery in adult mucopolysaccharidosis IIIB mice. Gene Ther 2007;14:1065-1077.
14. Furlan R, Pluchino S, Martino G. Gene therapy-mediated modulation of immune processes in the central nervous system. Curr Pharm Des 2003;9:2002-2008.
15. Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008;16:1018-1025.
16. Lu JF, Lawler AM, Watkins PA, et al. A mouse model for X-linked adrenoleukodystrophy. Proc Natl Acad Sci U S A 1997;94:9366-9371.
17. Furlan R, Pluchino S, Marconi PC, Martino G. Cytokine gene delivery into the central nervous system using intrathecally injected nonreplicative viral vectors. Methods Mol Biol 2003;215: 279-289.
18. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-428.
19. Aebischer P, Schluep M, Deglon N, et al. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2: 696-699.
20. Penn RD, Kroin JS, York MM, Cedarbaum JM. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery 1997;40: 94-100.